Sign in →

Test Code BA190 BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay

Reporting Name

BCR/ABL, p190, Quant, Monitor

Useful For

Monitoring response to therapy in patients with known e1/a2 bcr/abl (p190) fusion forms

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type


Advisory Information

This test should not be used to screen for bcr/abl fusions at the time of diagnosis; BADX / BCR/ABL1, Qualitative, Diagnostic Assay should be ordered for that purpose.

Shipping Instructions

Refrigerate specimen must arrive within 5 days (120 hours of draw), and ambient specimens must arrive within 3 days (72 hours) of draw. Draw and package specimen as close to shipping time as possible.

Necessary Information

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other bcr/abl-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Specimen Required

Submit only 1 of the following specimens:


Specimen Type: Whole blood


Preferred: EDTA (lavender top)

Acceptable: ACD (yellow top)

Specimen Volume: 4 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send specimen in original tube.

3. Label specimen as blood.


Specimen Type: Bone marrow


Preferred: EDTA (lavender top)

Acceptable: ACD (yellow top)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix bone marrow.

2. Send specimen in original tube.

3. Label specimen as bone marrow.

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time
Varies Refrigerated (preferred) 5 days
  Ambient  72 hours

Reference Values

The presence or absence of the BCR/ABL mRNA (bcr/abl) fusion form producing the p190 fusion protein is reported. If positive, the level is reported as the ratio of bcr/abl (p190) to abl with conversion to a percentage (ie, bcr/abl (p190) as a percentage of total abl).

Day(s) and Time(s) Performed

Monday through Friday a.m.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

81207-BCR/ABL1 (t[9;22]) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BA190 BCR/ABL, p190, Quant, Monitor In Process


Result ID Test Result Name Result LOINC Value
39470 BCR/ABL p190 Result In Process
MP002 Specimen Type 31208-2
19765 Final Diagnosis: 34574-4

Clinical Information

mRNA transcribed from BCR/ABL (fusion of the breakpoint cluster region gene [BCR]at chromosome 22q11 to the Abelson gene [ABL] at chromosome 9q23) is detected in all chronic myelogenous leukemia (CML) patients and a subset of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Although breakpoints in the BCR and ABL genes may occur in a variety of locations, splicing of the primary RNA transcripts result in only 8 fusion site variants (e1/a2, e6/a2, e13/a2, e14/a2, e19/a2, and e1/a3, e13/a3, e14/a3), which incorporate the entire sequence of the exons on both sides of the fusion site. The e1/a2 and e1/a3 fusion forms produce a 190-kDa protein designated p190. This bcr/abl protein form is found in approximately 75% of childhood ALL patients and approximately 50% of adult ALL patients, with the majority arising from e1/a2 mRNA. The p190 is also the predominant fusion form in a small subset of CML patients, although the vast majority of CML cases contain the p210 protein, typically from e13/a2 or e14/a2 mRNA fusions. Other fusion forms are very rare.


Quantitative reverse-transcription PCR (qRT-PCR) is the most sensitive method for monitoring bcr/abl levels during treatment. This test detects mRNA coding for the most common p190 fusion form (e1/a2).

Analytic Time

4 days

Reject Due To


Mild OK; Gross reject






Moderately to severely clotted

NY State Approved


Method Name

Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)


1. Hematopathology Patient Information (T676) in Special Instructions

2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request Form (T726) with the specimen (

Testing Algorithm

See BCR/ABL1 Ordering Guide for Blood and Bone Marrow in Special Instructions.